do not return unused solution to the original vial or attempt further storage Outer cardboard packaging may be disposed of in household waste or recycling in accordance with local policy, unless your trial team instructs otherwise Arrange a sharps bin and collection service via your GP surgery, local council, or as directed by your clinical trial team
The same FDA document mandates post-marketing trials to demonstrate that the novel agent does not increase cardiovascular risk by more than 30% compared to placebo (henceforth these trials were named cardiovascular outcome trial), if premarketing studies did not already demonstrate this
By activating GLP-1, GIP, and glucagon receptors simultaneously, it addresses appetite, blood sugar regulation, and energy expenditure in a way that single-pathway treatments simply cannot
This multi-system impact explains why GLP-1 medications produce benefits beyond just weight loss
If you still choose to use compounded tirzepatide, ask your healthcare provider if they have a trusted, preferred pharmacy they regularly use
ADDENDUM 24th November 2025: Today the results of the Novo Nordisk EVOKE 3 and EVOKE+ studies were announced today
